Evidence map›Paper›PMID 41179003›Full record

ArticleCureus2025

Coexistence Tumor of Craniopharyngioma and Pituitary Neuroendocrine Tumor: A Case Report and Literature Review.

Yohei Nounaka, Fumihiro Matano, Koshiro Isayama, Keiko Tomiyama, Chie Inomoto, Robert Y Osamura, Shigeyuki Tahara, Yasuo Murai

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yohei NounakaNeurological Surgery, Nippon Medical School, Tokyo, JPN.
Fumihiro MatanoNeurosurgery, Nippon Medical School Hospital, Tokyo, JPN.
Koshiro IsayamaNeurosurgery, Nippon Medical School Hospital, Tokyo, JPN.
Keiko TomiyamaEndocrinology, Diabetes and Metabolism, Nippon Medical School Hospital, Tokyo, JPN.
Chie InomotoPathology, Tokai University School of Medicine, Isehara City, JPN.
Robert Y OsamuraPathology, Nippon Koukan Hospital, Kawasaki, JPN.
Shigeyuki TaharaNeurological Surgery, Nippon Medical School Musashikosugi Hospital, Kawasaki, JPN.
Yasuo MuraiNeurological Surgery, Nippon Medical School, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acromegaly most commonly results from excess growth hormone (GH) produced by pituitary neuroendocrine tumors (PitNETs). Craniopharyngioma (CP) is an uncommon suprasellar tumor characterized by cystic change and calcification. The true coexistence of PitNET and CP is rare and poses diagnostic and operative challenges, particularly when lesions are spatially separated. A 72-year-old man was referred for a pituitary mass and clinical features suggestive of acromegaly (enlarged extremities, prominent supraorbital ridge, and jaw enlargement) without headache or visual complaints. MRI demonstrated two distinct lesions: a heterogeneous, mainly cystic suprasellar mass measuring 2.2×1.2×1.2 cm compressing the optic chiasm and extending toward the third ventricle, and a separate 1.7×1.2×1.1 cm intrasellar lesion extending into the sphenoid sinus. CT showed calcification within the suprasellar lesion. Baseline hormones revealed elevated GH (7.60 ng/mL) and IGF-1 (388 ng/mL; +5.7 SD) with inadequate GH suppression on oral glucose tolerance testing (nadir GH 2.68 ng/mL). An endoscopic endonasal transsphenoidal approach was undertaken. Intraoperatively, a white, soft intrasellar tumor breaching the dura and protruding into the sphenoid sinus was removed, and a separate, highly calcified suprasellar tumor was internally decompressed and dissected free; no macroscopic continuity was identified. Histopathology showed a densely granulated mixed somatotroph-lactotroph PitNET (immunoreactive for GH, prolactin, Pit-1, and alpha subunit; CAM5.2 perinuclear pattern <70%; Ki-67 <1%) and an adamantinomatous CP with wet keratin and calcified nests. Postoperatively, GH fell to 0.36 ng/mL and IGF-1 to 166 ng/mL (+1.2 SD). Transient diabetes insipidus occurred and was controlled with desmopressin. The patient was discharged without new neurological deficits, and an MRI at four months showed no recurrence. This case underscores the value of recognizing "separated" coexistence of CP and PitNET, in which discrepant imaging features (calcified, cystic suprasellar mass versus enhancing intrasellar lesion) can suggest dual pathology before surgery. Clear preoperative identification facilitates tailored resection strategies, allows focused manipulation of each lesion, and helps balance the competing priorities of gross-total removal and preservation of pituitary-hypothalamic function. Early biochemical remission of acromegaly and an uncomplicated radiographic course support the efficacy and safety of an endoscopic endonasal approach in selected patients. When intra- and suprasellar lesions demonstrate discordant radiologic characteristics in a patient with biochemical acromegaly, concomitant CP and PitNET should be considered. Distinguishing separated from admixed disease preoperatively can guide operative planning and reduce morbidity. Targeted endoscopic resection achieved prompt hormonal normalization and radiographic disease control in this patient, emphasizing the importance of individualized, anatomy-driven management and vigilant postoperative endocrine and imaging follow-up.

Indexed as

coexistence tumorcraniopharyngioma surgeryendoscopic endonasal transsphenoidal surgerygrowth hormone therapypituitary endocrine tumor

Identifiers

PMID41179003
PMCPMC12575402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.